Tessa Therapeutics Pte Ltd
8 Temasek Boulevard
#24-02 Suntec Tower 3
038988
Singapore
Tel: 65 6384 0755
Website: https://www.tessatherapeutics.com/
Email: info@tessatherapeutics.com
About Tessa Therapeutics Pte Ltd
Tessa Therapeutics is a clinical stage biopharmaceutical company with the scientific vision of revolutionizing the treatment of cancer by redirecting the body’s potent anti-viral immune response to recognize and kill cancer cells. Tessa’s core virus-specific T cell (VST) platform has shown compelling results in the treatment of solid tumors, and the company is building a portfolio of therapies addressing a wide range of tumors by combining the qualities of its T cell platform with complementary technologies.
YEAR FOUNDED:
2011
LEADERSHIP:
CEO: Andrew Khoo
COO: John Ng
CFO: Desmond Lim
CLINICAL TRIAL:
46 articles with Tessa Therapeutics Pte Ltd
-
Tessa Therapeutics Enters into Cooperative Research and Development Agreement (CRADA) with the U.S. National Cancer Institute
3/8/2023
Tessa Therapeutics Ltd. announced entry into a Cooperative Research and Development Agreement with the U.S. National Cancer Institute, part of the National Institutes of Health, to investigate TT11X, Tessa’s allogeneic “off-the-shelf” CD30.CAR-modified Epstein-Barr virus-specific T-cell therapy, in multiple subtypes of non-Hodgkin lymphoma.
-
Tessa Therapeutics Provides Strategic Outlook and Corporate Update for 2023
1/3/2023
Tessa Therapeutics Ltd. announced that the company will prioritize development of its allogeneic “off-the-shelf” CD30.CAR-modified Epstein-Barr virus-specific T-cell therapy platform, while seeking strategic options for the development of its TT11 autologous CAR-T platform with other companies.
-
Tessa Therapeutics Announces Updated Safety, Efficacy and Biomarker Data from Phase 2 Trial of Autologous CD30.CAR-T Therapy (TT11) in Relapsed or Refractory Classical Hodgkin Lymphoma
12/12/2022
Tessa Therapeutics Ltd. (Tessa) today announced updated clinical data from the pilot stage of the ongoing Phase 2 CHARIOT trial (NCT04268706) of TT11, the Company’s autologous CD30 chimeric antigen receptor T-cell (CAR-T) therapy, were presented in a poster and oral podium presentation at the 64rd Annual Meeting of the American Society of Hematology (ASH).
-
Tessa Therapeutics Announces New Clinical Data from Phase 1 Allogeneic Study Presented at 2022 Annual Meeting of American Society of Hematology (ASH)
12/10/2022
Tessa Therapeutics Ltd. announced enhanced clinical data from an ongoing Phase 1 study of TT11X, an allogeneic “off the shelf” CD30.CAR-modified Epstein-Barr virus-specific T-cell therapy being co-developed by Baylor College of Medicine and Tessa.
-
Tessa Therapeutics, Baylor College of Medicine Execute Agreement For Global Commercial Rights to ‘Off-the-Shelf’ CAR-T Platform
11/7/2022
Tessa Therapeutics Ltd. announced the execution of an exclusive agreement with Baylor College of Medicine for worldwide commercial rights to the allogeneic Epstein-Barr virus specific T-cell technology platform developed jointly by Tessa’s Scientific Co-Founder, Malcolm Brenner, M.D., Ph.D., and his colleagues Cliona Rooney Ph.D. and Helen Heslop M.D., D.Sc. at Baylor College of Medicine.
-
Tessa Therapeutics Announces Three Abstracts Highlighting Data from Autologous and Allogeneic Cell Therapy Programs Accepted for Presentation at 64th ASH Annual Meeting and Exposition
11/3/2022
Tessa Therapeutics Ltd. announced that three abstracts reporting data from clinical trials investigating the company’s autologous CD30.CAR-T therapy and allogeneic CD30.CAR EBVST therapy have been accepted for presentation at the 64th American Society of Hematology Annual Meeting taking place December 10-13, 2022, at the Ernest N. Morial Convention Center in New Orleans.
-
Tessa Therapeutics to Present at the Stifel Healthcare Conference 2022
11/2/2022
Tessa Therapeutics Ltd., a clinical-stage cell therapy company developing next-generation cancer treatments for hematological malignancies and solid tumors, announced that Thomas Willemsen, President and CEO, and Dr. Ivan D. Horak, Chief Medical Officer and Chief Scientific Officer, will present at the Stifel Healthcare Conference 2022.
-
Tessa Therapeutics to Participate in 2nd Annual Needham Biotech Private Company 1x1 Forum
10/6/2022
Tessa Therapeutics Ltd. announced that Thomas Willemsen, President and CEO, Wilson W. Cheung, Chief Financial Officer, and Ivan D. Horak, M.D., Chief Medical Officer and Chief Scientific Officer, will participate in the 2nd Annual Needham Biotech Private Company 1x1 Forum being held virtually October 18-19 2022.
-
Tessa Therapeutics Recognized in “Most Promising Off-the-Shelf Therapies” Category at Asia-Pacific Cell & Gene Therapy Excellence Awards 2022
9/14/2022
Tessa Therapeutics Ltd., a clinical-stage cell therapy company developing next-generation cancer treatments for hematological malignancies and solid tumors, announced that TT11X, the company’s allogeneic “off-the-shelf” CD30.CAR EBVST cell therapy, has been recognized in the “Most Promising Off-the-Shelf Therapies” category at the Asia-Pacific Cell & Gene Therapy Excellence Awards 2022.
-
This week's Movers & Shakers includes Tessa and Adial bringing in new CEOs, while other companies strengthened their regulatory and medical teams with key appointments
-
Tessa Therapeutics has tapped former Takeda executive Thomas Willemsen as the man to take its CAR-T portfolio forward.
-
Ryvu and Opthea have new funding to work with, Tessa Therapeutics and Enlivex kick off new trials and Revive Therapeutics amends the Phase III protocol for its COVID-19 hopeful.
-
Tessa Therapeutics Doses First Patient in Phase 1b Clinical Trial Investigating TT11 in Combination with Nivolumab for the Treatment of Relapsed/Refractory Classical Hodgkin Lymphoma (cHL)
8/17/2022
Tessa Therapeutics Ltd. announced the dosing of the first patient in a Phase 1b clinical trial investigating TT11, the company’s autologous CD30 chimeric antigen receptor T-cell therapy, in combination with Bristol Myers Squibb’s nivolumab as a potential second-line treatment for patients with relapsed or refractory CD30-positive classical Hodgkin lymphoma.
-
Tessa Therapeutics to Host Scientific Session on CD30 CAR-T targeting of CD30+ Lymphomas at the SDCT-REMEDIS Cell Therapy Conference 2022
6/13/2022
Tessa Therapeutics Ltd. announced that the company will host a scientific session during the SDCT-REMEDIS Cell Therapy Conference 2022 being held virtually from June 23-24, 2022.
-
Tessa Therapeutics, Synklino, Anagenex and Charm Therapeutics raise tens of millions of dollars in Series A financing.
-
Tessa Therapeutics Completes US$126 Million Financing Led by Polaris Partners
6/9/2022
Tessa Therapeutics Ltd., a clinical-stage cell therapy company developing next-generation cancer treatments for hematological malignancies and solid tumors, announced the close of a US$126 million Series A financing round.
-
Tessa Therapeutics Appoints Wilson W. Cheung as Chief Financial Officer
4/4/2022
Tessa Therapeutics Ltd., a clinical-stage cell therapy company developing next-generation cancer treatments for hematological malignancies and solid tumors, announced the appointment of Wilson W. Cheung as its chief financial officer effective April 1, 2022.
-
Clinical Catch-Up: December 11-17
12/20/2021
It was an enormously busy week with plenty of announcements from the American Society of Hematology meeting and numerous companies working to get the news out ahead of the holidays and year-end. Here’s a look. -
Tessa Therapeutics Announces Positive Data from Phase 2 Trial of Autologous CD30-CAR-T Therapy (TT11) in Relapsed or Refractory Classical Hodgkin Lymphoma at 2021 ASH Annual Meeting
12/13/2021
Tessa Therapeutics Ltd. (Tessa), a clinical-stage cell therapy company developing next-generation cancer treatments for hematological malignancies and solid tumors, today announced clinical data from the pilot stage of the ongoing Phase 2 CHARIOT trial (NCT04268706) of TT11, the Company’s autologous CD30 chimeric antigen receptor T-cell (CAR-T) therapy.
-
Tessa Therapeutics Showcases Positive Clinical Data from Phase 1 Study of “Off the Shelf” CD30 Cell Therapy at 2021 Annual Meeting of American Society of Hematology (ASH)
12/11/2021
Tessa Therapeutics Ltd., a clinical-stage cell therapy company developing next-generation cancer treatments for hematological malignancies and solid tumors, announced clinical data from an ongoing Phase 1 study of TT11X, an allogeneic “off the shelf” CD30.CAR-modified Epstein-Barr virus-specific T-cell therapy being co-developed by Baylor College of Medicine and Tessa.